Vegzelma™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Metastatic Colorectal Cancer,Vegzelma (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer.,Locally recurrent or metastatic Breast Cancer,Vegzelma (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated. (see Section 5.1 Clinical Trials).,Advanced, metastatic or recurrent non-squamous Non-Small Cell Lung Cancer (NSCLC),Vegzelma (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous, non- small cell lung cancer.,Advanced and/or metastatic Renal Cell Cancer,Vegzelma (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer.,Grade IV Glioma,Vegzelma (bevacizumab) as a single agent, is indicated for the treatment of patients with Grade IV glioma after relapse or disease progression after standard therapy, including chemotherapy.,Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer,Vegzelma (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.,Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer,Vegzelma (bevacizumab), in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other VEGF-targeted angiogenesis inhibitors. Vegzelma (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens, and have not received any prior anti-angiogenic therapy including bevacizumab.,Cervical Cancer,Vegzelma (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. Vegzelma (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

Source: ARTG

• Shelf lifetime is 48 Months
• Store at 2 to 8 degrees Celsius
• Protect from Light; Do not Freeze

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, concentrated
• Intravenous Infusion
• Clear to slightly opalescent, colourless to pale brown, sterile solution

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 1 vial

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under PBS item codes 12508H (Opens in new tab) and 12479T (Opens in new tab). Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: Bevacizumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).